Home / Transcripts / Omada Health, Inc. (OMDA) · November 5, 2026

Omada Health, Inc. (OMDA) Earnings Call Transcript

November 5, 2026

NASDAQ US Health Care Health Care Providers and Services earnings 46 min

Earnings Call Speaker Segments

Craig Gracey executive
#1

Thanks, everyone. Good afternoon, and thanks for joining Omada Health's third quarter 2026 earnings conference call. Joining me are co-founder and CEO Sean Duffy, President Wei-Li Shao, and CFO Steve Cook. Before we start, I'd like to mention that we'll be covering non-GAAP financial measures, which we think are useful for assessing how Omada is performing. You can find information on how these compare with our GAAP measures, including reconciliations, in the press release posted on our website. We'll additionally be sharing forward-looking statements grounded in what we currently expect and assume; those carry risks and uncertainties, among them the factors enumerated in our press release as well as the risk factors contained in the documents we file with the SEC. Outcomes in reality might vary materially, and we undertake no duty to revise such forward-looking statements. On that note, I'll hand things over to Sean.

Sean Duffy executive
#2

Thanks, Craig. Good afternoon, everyone, and I appreciate you joining us. We've just reported the strongest quarter in our history, and we are raising our guidance for the entire 2026 fiscal year. Q3 marked another period of solid performance. We delivered record revenue for a quarter, saw gross margin keep improving, and posted our most profitable quarter to date. Revenue climbed 34% compared with the prior year, reaching $91 million. Gross margin was 76% under GAAP and 78% on a non-GAAP basis, up from 66% and 68% in the same period last year. In addition, we recorded quarterly net income of almost $7 million—a record—along with adjusted EBITDA of $12 million. Our diabetes and hypertension programs delivered another productive quarter, posting the highest year-over-year growth across all our programs. Strong enrollments early in the quarter, along with a mix shift toward our higher valued programs, helped revenue beat our expectations. The cardiometabolic platform we've built keeps delivering for our members and for our customers. I'd also like to take a moment to share a member quote that captures what matters most to us at Omada — the people we serve. "I'm so excited. I have changed what I am eating and the way I'm exercising differently. My new labs today are improved, and my A1C is 6.6%, down from 7.3% three months ago. My cholesterol also improved. There's more I now know about diabetes—how to keep tabs on it and handle it day to day. I feel sure of myself with the tools, blood glucose checks included, and asking questions of my health coach and the diabetes coach has done a lot for me emotionally." That kind of story is the reason our company exists. While we go through our robust financial results, let me remind everybody that behind each of those figures sits a human being striving toward better health, trying to keep disease from advancing, and seeking the support they require in the gaps between doctor appointments. That mission is what continues to propel us. Last, as we said a quarter ago, Wei-Li Shao takes over as Omada's Chief Executive Officer on January 1, 2027, and I will move into the Executive Chair role. I’m eager to remain deeply engaged, with my attention on the long-term mission, the partnerships that matter most, and our strategic priorities. Omada began 15 years ago because I held a straightforward conviction: the interval between physician appointments—where health is either gained or lost—was worthy of genuine care. Seeing what this team has accomplished leaves me feeling deeply humbled. Although my role in the company is changing, my dedication to this mission has not shifted at all. I have tremendous faith in Wei-Li and in this team. The foundation is solid, and I’m excited to continue building on it alongside everyone. With that, I’ll turn things over to Wei-Li.

Wei-Li Shao executive
#3

Sean, thanks — and good morning, everyone. Sean, I appreciate your seven years of partnership, the foundation you built, and your continued leadership of Omada alongside me in the Executive Chair role. I'm proud of what we achieved this quarter; we closed Q3 with more than 1.1 million total members, a 36% year-over-year increase, which shows ongoing demand for our cardiometabolic platform. Growth continued to be led by our diabetes and hypertension programs. Members remained with us for longer periods, and our capacity to deliver personalized care at scale achieved a new level of efficiency. During the previous quarter's update, we noted that our collaboration with Health Care Service Corporation, or HCSC — among the biggest Blues plans nationwide — had been expanded via an arrangement bringing our prevention and hypertension offerings to its fully insured book across three more states. At launch in 2027, that effort is anticipated to potentially reach roughly 1.5 million additional covered lives. Within the fully insured segment, this program sits at the benefit level, so clinically eligible members may sign up on their own as soon as it goes live, with no need for a later employer sales cycle. Turning to the PBM side, we hold commercial ties with the country's three biggest PBMs, which collectively handled an estimated 80% of prescription claims during 2025. Right now, our prescribing program is live in the market with Optum. Through these relationships, we have the widest distribution for our programs in Omada's history. Working with a varied set of partners and channels also gives us visibility into many different employer needs and priorities. I'd like to share what we're observing in the marketplace and how that is influencing our outlook. The GLP-1 market is still dynamic. Given the scale of the commitment, the variety of solutions, and how important it is to get these decisions right, a number of employers have been devoting more time to making choices about GLP-1 coverage and obesity care. Healthcare costs are climbing as well, which is putting pressure on health plans, PBMs, and employers. Buyers are focused on outcomes and ROI to a greater degree than ever. Omada has long had a track record and reputation for publishing peer-reviewed research covering both our outcomes and our ROI. Evidence of this kind has consistently been at the heart of Omada's approach, and we think it mattered during this year's selling cycle; we saw both of those factors push the selling season further into Q4. Covered lives provide the base, and enrollment is the route by which those lives turn into members. Two developments influenced enrollment and growth in this quarter. The first, and the biggest, is how strong our cardiometabolic core is. Our diabetes and hypertension programs, together with the wider suite surrounding them, once again produced solid results in Q3. A shift in the mix toward these programs helped drive our revenue growth. With these programs, members have generally remained engaged with us for a longer period, given how chronic the disease is, and that supports a higher lifetime value for Omada. The second factor is how quickly enrollment is moving. Robust sign-ups during July and August helped us reach record revenue in Q3. As we've noted previously, sign-ups usually reach their high point in the first quarter, when employers introduce new benefits, and then decline over the remainder of the year; for Q4, we expect a sequential decrease in new enrollments, consistent with that typical pattern. The year-over-year picture is a different story; during H2 2025, we brought on a substantial number of new customers and members through a new GLP-1 offering from a channel partner we already had, one that bundled our prevention and weight health program, and that drove unusually robust enrollment across a stretch that isn’t representative of our normal seasonality. It’s in member engagement that the staying power of our model becomes visible. As we told everyone at Investor Day in September, member retention now stands at 58%, an increase from 43% in Q4 of 2024. Much of that gain comes from our shift toward diabetes and hypertension, categories where members have historically remained with us longer, along with ongoing upgrades to our member experience and app. By the close of Q3, average tenure in our program hit a record of about two years and four months, which is 10% higher year-over-year and more than 30% above where it stood three years ago; that works out to an increase of approximately two and a half months versus a year ago. When members stay longer, they have the time to convert early progress into durable health improvements. We deliver more intensive clinical care during the early phase to help members build solid habits, and we keep adjusting their care as those habits become established. Once members are able to maintain their progress with support that is less frequent and less intensive, the cost of serving them goes down and margins rise, while billing stays linked to the care we keep providing. We now also have fresh evidence of the clinical value our care delivers. New peer-reviewed research that came out recently found that people enrolled in our GLP-1 Care Track lost almost two times as much weight as GLP-1 users who got care elsewhere than Omada at the 12-week mark — an average of 6% weight loss compared with 3.3% — and on average they also saw about double the drop in body fat, along with better retention of muscle mass. These results underscore how much value comes from pairing medication with the type of support our GLP-1 Care Track provides. To deliver these results consistently, we have to keep advancing both our care model and the technology underpinning it. As we've noted previously, 2026 looked to us like our most innovative year to date. Several of this year's improvements were introduced during Q3. We upgraded onboarding so members can begin care sooner, with goals customized to their situation. As care proceeds, tailored reminders and recommendations give them timely guidance and help them remain on track. We also beefed up nutrition support and meal reviews that blend human and AI feedback, which helps members develop healthier eating patterns that can underpin lasting gains in their health. Our efforts in cholesterol management, GLP-1 prescribing, and Flex Care are designed to deepen engagement further in 2027. Our aim is to extend personalized care to more members as we scale. Like we told everyone on Investor Day, automation plus AI now let our care teams spend more time applying clinical know-how and personalizing care for each member. Because of that, each care team can handle a larger panel of members while still providing care that's more tailored than before. On a trailing 12-month basis, our non-GAAP cost of revenue per total member — that's how we measure cost to care — hit a record low of $81 in Q3, compared with $85 in Q2 and $94 in Q3 2025. What we've built at Omada really comes through this quarter. Our commercial partnerships provide wide reach, and growth has come from our cardiometabolic programs. Members are staying with us longer thanks to our program mix, and our cost to serve has come down — all of it feeding into another strong quarter. On our platform, customers are able to select the programs that best suit the populations they serve. A study that came out not long ago shows that roughly 188 million insured adults in America have a condition we treat, and a third of our customers already work with us on more than one condition. This year we rolled out prescribing offerings and brought cholesterol in as a condition area, which gives our customers a broader set of choices. Our financial position also strengthened during this quarter. We've now been profitable for two straight quarters, we carry a strong balance sheet and no debt, and that hands us genuine flexibility in deploying capital; our plan is to keep investing in our care model, our technology, and commercial reach, while staying open to other opportunities that make the business stronger. Now that I've stepped into the CEO role, my focus is straightforward: execute with discipline, remain close to our partners and members, speed up innovation, and keep advancing our mission of bending the curve of chronic disease. Sean, thanks once more, and to our teams across Omada and our channel partners, thank you for all that you do. Together, we're changing people's lives for the better; with that, I'll hand things to Steve, who will walk through Q3 financial performance in more detail.

Steve Cook executive
#4

Thanks, Wei-Li. Hi, everyone. Let me begin with revenue. Revenue for Q3 came in at $91 million, which is a 34% increase year-over-year and roughly 4% higher sequentially versus $88 million in Q2. We beat our expectations on revenue for three reasons: first, robust enrollments early in the quarter meant those new members added revenue across a greater portion of the period; second, our mix moved toward programs with higher value; and third, engagement rose throughout our member base. Combined, those factors produced the quarter's outperformance and underpin our raised full year revenue outlook. Turning to the fourth quarter, we expect the pace of new sign-ups to slow from the prior quarter, consistent with typical seasonal patterns; on a trailing 12-month basis, revenue per total member came to $294 during Q3, compared with $280 in the same quarter a year earlier and $284 in Q2. That reflects the growing mix of our pricier diabetes and hypertension offerings, partially offset by less frequent billing among members who have been with us longer; this figure may move somewhat higher or lower from one quarter to the next; during Q3 we brought in about 43,000 net additional members, bringing our total membership to a record 1,134,000, a 36% increase year-over-year. To keep our growth going, our commercial teams are concentrated on expanding the pipeline and securing new business for the upcoming benefit year while the selling season is still underway. Now on profitability: GAAP gross margin came in at 76% for Q3, compared with 66% in the same quarter a year earlier. Non-GAAP gross margin reached 78%, versus 68% previously. The margin improvement in this quarter stems from a reduced cost to serve our members, helped by lower care team delivery costs and by our longer-tenured cohorts maturing; seasonality also plays a part, because enrollment volume drives care team and device costs, and historically those costs peak in the first quarter. Now let's turn to operating expenses. GAAP operating expenses came in at 71% of revenue, versus 70% in the prior-year period. Non-GAAP operating expenses were 64%, down from 65%. The non-GAAP improvement comes from the same drivers we've been citing all along: scaling through channel partnerships, squeezing more out of the sales force we already have, disciplined spending everywhere else in the business, and AI. The quarter's expenses got a lift from the timing of Q3 headcount additions; in Q4, we anticipate R&D expenses will rise as we bring on staff to support development of our platform. With that, we move to the bottom line. In the third quarter, GAAP net income came in at just under $7 million. That compares to a GAAP net loss of about $3 million in Q3 of the prior year — roughly a $10 million improvement. Adjusted EBITDA for Q3 reached $12 million, up around $10 million from a year earlier and a record for any quarter at Omada, which works out to an adjusted EBITDA margin of about 14%. Those figures reflect growth in revenue along with a lower cost to serve, plus the seasonal expenses and hiring timing I mentioned earlier. Our stronger profitability has kept contributing to a solid balance sheet. We ended Q3 with approximately $243 million in cash and cash equivalents, and we continue to carry no debt. Turning to the full-year outlook: based on Q3's performance and what's visible for Q4, we have enough confidence to raise our 2026 guidance for both revenue and adjusted EBITDA. For the full year, revenue is now expected to land between $344 million and $346 million, up from the earlier $334 million to $340 million. At the midpoint, that implies roughly 33% revenue growth over 2025. We're also lifting full-year adjusted EBITDA guidance to $32 million to $34 million, versus the previous $21 million to $27 million. At the midpoint, that works out to an increase of about $27 million compared with 2025—roughly 5.5 times the adjusted EBITDA we posted in 2025. Several factors are influencing our view of the fourth quarter. Our guidance assumes fourth-quarter revenue will come in below third-quarter levels, reflecting the weaker new enrollment and engagement we typically see during the holiday period; we expect the bulk of revenue to come from continued engagement among members already with us; and regarding adjusted EBITDA, the raised outlook reflects results achieved so far this year along with the operating leverage built into our model. For Q4, we anticipate adjusted EBITDA will come in lower than Q3, since we're adding R&D staff to advance work on our platform and expanding care team personnel ahead of the 2027 benefit launch. In summary, Q3 proved a robust period for Omada, delivering 34% revenue growth, our best gross margins, and the most profitable quarter we've had so far. Given those results, we are lifting our outlook for the full year. With that, we'll now take questions.

Ryan MacDonald analyst
#5

Hello, and thank you for the questions—congrats on the strong quarter. Wei-Li, perhaps begin with you, and Sean as well—apologies, both of you. You mentioned selling-season activity, with GLP-1 coverage choices being top of mind for buyers at present, though that may be stretching or pushing the selling season further into Q4 compared with last year. Could you discuss, when it comes to coverage adoption or adding GLP-1 coverage versus discontinuing it, which of those scenarios is more favorable for Omada, and where things stand in those conversations with your clients? Thanks.

Wei-Li Shao executive
#6

Hi, Ryan. Good to hear from you. Appreciate the question. On the GLP-1 marketplace, you've got it right. That market remains in flux, and our employer clients are definitely taking whatever time they require to make those specific choices. As you mentioned, we've seen some reports indicating that GLP-1 coverage within the employer marketplace appears to be declining as we approach 2027. Pinpointing or describing the precise quantitative extent of that trend is difficult — I suppose once the new year arrives we'll find out where the numbers really land, but it does appear to be occurring. To answer your question about what works in Omada's favor, I'd frame it this way: we deliberately designed how we go to market and our strategy around GLP-1 products so that it spans both outcomes of the coverage decision. In other words, when employers do cover GLP-1s, we offer a set of prescribing and lifestyle support offerings—our GLP-1 Care Track solutions—that are covered by a number of PBMs and health plans, so we're able to serve those employer clients through that route. And for employers who decide against covering GLP-1s, we considered this exact scenario a couple of years back and anticipated it might well happen, and at that point we came up with the concept for our GLP-1 Flex Care products, which we announced and brought to market earlier this year, in March. That program stands out because it delivers the same prescribing clinical expertise, services, and lifestyle support to GLP-1 users; when an employer isn't covering the GLP-1, that employer recognizes that no matter what coverage decision they make, their workers are more and more obtaining GLP-1s from other sources. That's interesting fact point number one. Interesting fact point number two is the response as we educate and sell the GLP-1 Flex Care product in the marketplace. Employers grasp the potential ROI upside and the program's merits for a couple of reasons. The first is that you get amplified weight loss. The second point is that the weight loss is better in quality — which means more fat is lost while lean mass is preserved. The third is that patients or employees who ought to be on GLP-1s show better adherence. The fourth is that once GLP-1 use ends, there is basically little to no weight regain, as the data from our 12 months shows. They look at those results and ask, "Gosh, we don't cover GLP-1s, but might there be potential ROI in offering Omada as clinical services and support for our employees who are taking GLP-1s, so that we can capture that ROI?" That interest seems to be growing. Although this year has only involved partial selling for us, one illustration and piece of evidence is that we brought on board a fairly sizable financial institution at midyear, and that client has in fact decided to speed things up and go live within the year. Responses coming from members are moving in a favorable direction; we're eager for 2027 in the sense of being able to serve employers and help generate value for them whether they provide coverage or not, and we anticipate a complete selling-year cycle for our GLP-1 Flex Care program.

Ryan MacDonald analyst
#7

Thanks for all that detail, Wei-Li. And then, Steve, perhaps as a quick follow-up, could you clarify what was said about total member count for the fourth quarter that's implied by the guidance? I believe earlier Wei-Li may have mentioned in his prepared remarks that declines were, as you put it, moderating. Could you expand on that a little for us? Thanks.

Steve Cook executive
#8

You've got it exactly, Ryan. Relative to last year, we saw an acceleration during the back half of last year while we were rolling out our new GLP-1 product alongside one of our new channel partners. 2026 looks more like our usual seasonality, in which a large influx of members arrives in the first quarter and then begins to moderate as the year progresses. What's currently implied is that on a total member basis we'll step down slightly as we head into the fourth quarter, and our focus is squarely on execution and on building a pipeline with our employer clients along with our health plan and PBM partners, so that we head into 2027 with strong momentum.

Ryan MacDonald analyst
#9

Great. Thanks for the additional detail. Appreciate it.

Carly Buecker analyst
#10

Hello, this is Carly calling in for Saket. Thanks for taking our question. Steve, when we consider the growth drivers for 2027 and past that, given your target of 20% plus growth, there is plenty to discuss — the white space out there in the market, a growing Omada platform, more uptake of higher-priced programs, and additional commercial partnerships. Could you unpack that 20% plus growth a bit for us? What portion might come from member growth as opposed to ARPU growth, and which puts and takes could shift that growth formula from year to year as various products and commercial partnerships ramp up?

Steve Cook executive
#11

Carly, thanks for the question. Something we devoted considerable time to, specifically at Investor Day, was really concentrating on the three main growth levers in our business: keep expanding covered lives, keep driving an improved enrollment rate, and keep focusing on engagement while making sure that folks remain in program longer. Regarding how the three are distributed, next year we're going to be focusing on driving all three. As Wei-Li noted earlier, we've added 1.5 million covered lives with HCSC. Then, heading into next year, we have a number of investment bets aimed at continuing to improve enrollment rate efficacy through our email channel, along with continued use of direct marketing. That channel keeps bringing us incremental enrollments — over the past 12 months, we've sent more than 100 million emails. We keep running A/B tests within that medium, bringing more people in on a covered lives basis and enrolling more people in aggregate as each quarter goes by. Wei-Li brought this up earlier in the prepared remarks as well: at this point, participants in our programs stay with us for an average of two years and four months. That figure is 10% higher than it was a year ago, and it reflects our ongoing efforts to get people using more than one product, along with a growing number of diabetic and hypertensive members in our programs — these rank among our most expensive offerings and carry the strongest LTV, since members remain enrolled longer. Looking ahead to next year, we'll keep concentrating on expanding our prescribing capabilities. That will be our most expensive product. With additional of those members beginning to move through our customer base, you should expect overall trailing 12-month revenue per member to rise; next year our attention will center on precisely the core drivers we presented during Investor Day. Thank you.

Carly Buecker analyst
#12

That's really useful. Thanks.

David Larsen analyst
#13

Hi there, congrats on the strong quarter. Could you spend a moment on the MSK business, behavioral health, and women's health? There's clearly a lot of demand in obesity health and GLP-1s, but those appear to be really important markets. Thanks so much.

Wei-Li Shao executive
#14

Hi, David. This is Wei-Li. Appreciate the question. When it comes to those three categories, each one is quite distinct, so let me give you some context on a few of them. On MSK, yes, we've operated in that business for several years now. It represents a fairly small share of our revenue, 5%, yet it's a strategically important asset for our cardiometabolic strategy. What does that mean? Our approach isn't really about standalone MSK; it's about how we keep serving with a better experience and better outcomes and ROI for our cardiometabolic segment. We know, for instance, that among people with diabetes, about 40% have a bona fide MSK condition, which may not come as a surprise given what's happening metabolically. Frequently, people with diabetes are overweight or obese, so there's substantial weight on hips, backs, and knees, and that produces an MSK condition. That matters because, if mobility is reduced or the ability to exercise is reduced, it's one lever that's taken away from the patient or the member to improve their diabetes condition. Our strategy with MSK really is to fully integrate it with our cardiometabolic platform for the reasons just mentioned, and we'll keep investing in integration; we have some new things coming next year that we hope to discuss with you after the turn of the year, but rest assured that's one particular area that warrants continued investment. As for the other areas, like menopause, this one's kind of interesting on the women's health side. Obviously, when you look at GLP-1 utilization and demographics broadly across the United States, most users are women falling into a particular age group that is perimenopausal. We're acutely aware of that. We actually run outreach campaigns aimed specifically at the perimenopausal, menopausal segment, precisely because, whether or not they're on GLP-1s, there are a lot of basically biochemical changes and hormonal changes happening in the body that people want to learn about, and so that's been resonating strongly with our customers; then we also, as part of that, have women's health or menopause learning tracks to help the female population within our GLP-1 and non-GLP-1 programs. Suffice it to say that, when we see these things overlap significantly with our cardiometabolic segment as well as our strategy, we fold them in as necessary to best serve the outcomes and ROI for our members and our clients.

David Larsen analyst
#15

Thank you so much. What a great quarter. Congratulations.

Ayush Vyas analyst
#16

Hi, everyone, Ayush here filling in for Elizabeth. Appreciate you taking my question, and congratulations on the quarter. In your prepared remarks you pointed out that July and August enrollment was strong, and that you saw gains from onboarding changes rolled out in Q3. I'm just wondering, did quicker onboarding meaningfully reduce the span between enrollment and the first billing event, and perhaps play a part in any of the revenue upside this quarter, or was the benefit mainly more people signing up?

Steve Cook executive
#17

No, you've got it exactly right. Earlier in the quarter we made a tactical shift so we could enroll people as they signed up, rather than in weekly groupables. Because of that, we immediately saw more pickup and conversion feeding into our enrollment rate gains. That turned into immediate conversions being realized, particularly earlier in the quarter, and that is part of what drove the revenue beat in the quarter.

Ayush Vyas analyst
#18

Understood. Thank you.

Sean Dodge analyst
#19

Thank you. Perhaps if we return to the selling season and consider it across all of Omada, including the GLP-1 offering and your other products. I realize quite a few of your bigger initial PBM relationships are still maturing, but any updates you could give on how the selling season overall has gone or is going, and any early estimate you can offer about how much covered lives might grow as we head into next year?

Wei-Li Shao executive
#20

Hello, Sean. This is Wei-Li. I appreciate the question. A few things — I'll address covered lives as we wrap up the closing season, but first let me give a bit of framing and context. As we said in the prepared remarks, we're watching and paying close attention to a couple of developments in the external market. The first is the dynamism in the GLP-1 marketplace and the financial decisions employer clients must make. The second, naturally, is the overall pace at which healthcare costs are rising, and how health plan buyers or health services buyers are deliberating somewhat more. That matters because both of those factors are pushing the selling season later into Q4. That's something we typically don't see, which is why we raised it, but it's worth noting, since it's difficult to quantify or characterize precisely where we'll end the year at this moment, because we still have a substantial amount of pipe left to close given the extension of the selling season and closing season. I can't characterize the actual amount. Obviously, once we get past the new year, we'll revisit this and add a bit more color on that. I understand and appreciate the question regarding what it means for 2027. Rather than giving a quantitative answer, maybe I can offer some color on precisely what happened in Q3 and how Q4 is shaping up as it relates to the selling season or our pipeline. We entered the selling season, or really the selling year this year, with two primary objectives aligned to our strategy. Not surprisingly, the first is multi-condition sales, and the second is diversifying our channel mix across our partners; we're executing on both. On the multi-condition front, even in Q3, consistent with what we've said previously, of the new deals we've closed, 40% to 50% are for multi-condition or more products being purchased by the buyer. We like that because it's obviously better for us, but most importantly, it's better for our clients, because people with cardiometabolic disease often suffer from two or more conditions, and so we're simply able to provide a better, seamless care experience. Regarding the channel mix, when you consider our pipeline for Q3 and, clearly, the later-stage deals in Q4 that we are still working through, the distribution is fairly balanced. Again, that mirrors CVS and Optum rising somewhat more than they did in earlier periods, along with our existing channels into which we continue selling. Across the channels in our pipe, distribution is fairly balanced, and truly both of our results on that front—channel mix and multi-condition—reflect the sales force's intent as well as its execution. There's more to come. Keep watching how the pipe ultimately takes shape as we move into the new year.

Sean Dodge analyst
#21

That's excellent. I appreciate all the detail you provided. You also mentioned the win with HCSC's fully insured book, where your products are built in at the benefit level. I realize it's still early days, but how significantly do you believe that kind of embedded position could lift your enrollment or conversion rates, and is HCSC the only payer you currently have this sort of relationship with, and what does the pipeline look like for bringing on more?

Wei-Li Shao executive
#22

Perhaps it would help to describe how the deal is structured in terms of our go-to-market approach. I believe that may help address the question regarding 2027 and what to expect. Essentially, an expansion of roughly about 1.5 million lives into three additional states through our hypertension and prevention programs will start going live directly on January 1, which means we'll begin working in partnership with HCSC to reach out directly to the members and covered lives within that 1.5 million. Now, we won't do it all at once; that will phase throughout the entire year, and we don't expect all the lives to enter the marketplace immediately. They'll again be phased throughout the year, and we should see results from that next year, and we look forward to reporting on it. Regarding other lines of business, your question about whether we have other direct-to-member type arrangements, such as fully insured books of business elsewhere, the answer is yes. We have those with some other fairly large-scaled partners. It's an approach we're familiar with and that we have had success executing, and we can certainly follow up with more details if you'd like, but we do have those in other books of business as well.

Sean Dodge analyst
#23

No, that's great. Thanks again.

John Pinney analyst
#24

Hi, yeah. John Pinney here, sitting in for Richard Close. Appreciate the questions and congratulations on the quarter. I suppose I'd like to dig deeper into those stronger in-year enrollments you had. You mentioned it got a bit of a boost from real-time enrollment as opposed to the weekly batching. I guess, is there anything you did differently this year when it comes to outreach and to the covered lives base that helped with that midyear — anything you'd say you did a little better than last year that produced these improved enrollment results?

Wei-Li Shao executive
#25

Hi, John. This is Wei-Li. Thanks for asking about enrollment performance. As for what we're doing differently — are we doing something differently? Maybe I can give you some historical context on year-to-date performance. Our yield rate, or enrollment rate, year to date has grown roughly 10% versus last year, and we definitely saw that carry through in Q3 as well; it was good to see that persistent effect. That certainly contributed some tailwinds to the Q3 performance. As to whether we're doing anything differently, and what that means going forward: each year we go through a fairly extensive A/B testing optimization process; it typically starts in H2 after we see the enrollment and yield performance in H1; we've done that this year as well. We've run dozens of tests, across email, direct mail, and other channels. We've been doing more in the social channel, and we're seeing some moderate uptake and improvement there and performance there, but nothing significantly material to note. It represents an area where we are experimenting and seeing some green shoots. On overall optimization of our campaigns, like I said, that's an exercise we started in H1 — or H2, rather — and we'll continue throughout the end of the year. We'll look to characterize a bit more about that enrollment yield improvement next year at the appropriate time.

Steve Cook executive
#26

The sole point I’d add is that, among the 25 million covered lives, we’re deploying direct mail quite selectively. On those campaigns, we were able to monitor ROI plus CAC LTV directly. For certain subpopulations that may lack email access, we have observed some effectiveness from direct mail in bringing more people through the door, and we will focus specifically on higher-acuity conditions—particularly diabetic and hypertensive populations—where we can reach out to them directly and bring those individuals in; that has been one more tool in the toolkit, and we have seen some progress there across 2026 as well.

John Pinney analyst
#27

Okay, thanks for that extra detail. I suppose I have one more question to ask. Steve, you brought up how every year you ramp up care team staffing as the new year approaches. What I'm somewhat wondering is where things stand with your care team at this moment. Would you say you're basically at capacity and actually need to build additional capacity, or is this simply the usual preparation for a new benefit year? Any thoughts you could share on that would be helpful.

Steve Cook executive
#28

No, when we compare year over year, we've achieved a great deal of efficiency throughout core operations and standardized work. Jennifer Peck, who serves as our chief care delivery officer, has done a fantastic job making that organization highly efficient. Now that we're using more AI, we've in fact seen net headcount go down year over year there. We do intend to potentially ramp up a modest amount for Q1, since we do observe a Q1 spike when it comes to net new enrollments, but all of that supports reaching our longer-term gross margin target of 80%. We genuinely believe that across the better part of the last five years, we've truly refined how we staff that organization, allowing us to align supply and demand in a really optimal way over time, and we feel good about how we're set up heading into next year.

John Pinney analyst
#29

All right. Thank you. Congratulations once more.

Wei-Li Shao executive
#30

Hello, Day. This is Wei-Li speaking. I appreciate the question. It's a significant one, I believe, because clearly, with healthcare costs speeding up and climbing, employers, health plans, and PBMs must do their jobs and are examining extremely, extremely carefully the value when it comes to the return on investment or the savings any healthcare provider program is able to deliver, and Omada certainly participates in those negotiations and discussions as well. To answer your question directly, are we seeing additional performance guarantees, outcome guarantees, or ROI guarantees? My response would be that, for roughly the last 3 or 4 years, they've likely grown increasingly common in our negotiations and discussions, and that is something we have been dealing with during that stretch. I think it's also worth noting, to set the stage and the frame, that we hold a reputation in the marketplace for being evidence-based and running plenty of clinical trials along with other kinds of observational trials. We have 30-plus some odd peer-reviewed publications, examining not just the outcomes of our programs but the economics too. I bring that up because, when we enter these negotiations, if there's a need to take on some form of performance or ROI or outcomes guarantee, we truly rely on our data, and that lets us assume the appropriate risk relative to the outcomes we can deliver, which our aim, of course, is to satisfy the expectations of our buyer clients. This isn't a new development, and it isn't a fixture. Obviously, with rising healthcare costs, we encounter a bit more of it, but we remain fairly steadfast on our outcomes and our economics, and we believe we're achieving some success there.

Gene Mannheimer analyst
#31

Thanks. Good afternoon, and congratulations on the strong quarter. I'd like to explore that gross margin a bit further, since it was really impressive. You made a comment — I believe it was Steve — but as your members keep maturing, and assuming duration remains roughly at the same level or gets better the way it has been, would it be fair to say gross margin will keep trending upward from there? My assumption is that this is one of the pieces in reaching your longer-term 80% target, and I'm curious whether that's the primary driver or whether other components play a role. Thank you.

Steve Cook executive
#32

Gene, thanks for the question. There are certainly many drivers. Let me begin with the top line. Most important on the top line is our ongoing push for multi-product adoption — bringing in more people who are diabetic and hypertensive and now reaching the market with our prescribing capabilities. As the mix of those conditions improves across our overall member base, that raises gross margin, overall LTV, and gross profit dollars over time. On the cost side of things, there are three levers: our care teams, making them more efficient, which we discussed a bit earlier; continued negotiations across our supply chain with our devices as well as our shipping partners; and then, more recently, our use of AI to make our care teams more efficient and more effective. Those four are the main components that directly drive it. Then, to your point, the longer people stay in the program — we're seeing folks in their fifth years, fifth and sixth years with Omada — they're further along on the engagement curve. They don't bill as much revenue when they're that far out, but they're among our highest gross profit members, because there's very little incremental cost once you're that far out on the tenure curve. We really like those members, because we're still taking care of them, we're making sure they're healthy, but they're driving incremental dollars that go directly to the bottom line.

Gene Mannheimer analyst
#33

Understood. Many thanks.

Corey DeVito analyst
#34

Hello, Corey DeVito speaking on Stan's behalf. Appreciate you fielding my questions. You attributed Q3 growth to diabetes and hypertension. So did GLP-1 Care Track membership increase versus Q2, and what number of employers have enrolled for 2027 via Flex Care or Lilly Employer Connect? Thank you.

Wei-Li Shao executive
#35

Hi there, Corey. This is Wei-Li. I'll take the second question regarding 2027 and how many employers are signed up, that sort of thing. As I said earlier, the closing and selling season is running later into Q4 than usual, so it likely wouldn't be wise for me to put a quantitative label on total covered lives going into 2027, given that a fair number of late-stage deals are being actioned right now. No comment possible there. I look forward to characterizing more once 2027 arrives, and that applies to any program, GLP-1s included.

Operator operator
#36

Thank you. That brings the question-and-answer portion to a close. We appreciate everyone taking part in today's conference. With that, the program has ended, and you're welcome to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Omada Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Omada Health, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.